Pharma Braces For Potential Landmark Moment For US Drug Price Controls

US drug pricing legislation that has picked up momentum could stymie R&D investment and curb the revenue tail for some big drugs, industry says, but CEOs also expect they can navigate the challenge. 

capital building
Drug pricing legislation has picked up momentum in the US • Source: Shutterstock

Industry's attention is focused on Capitol Hill as momentum appears to be building for potential US drug pricing legislation that would allow the US government to negotiate drug prices for the drugs it spends the most on under Medicare Part D beginning in 2026 and Medicare Part B in 2028.

More from Drug Pricing

More from Scrip